Literature DB >> 11225507

The epidemiology of generalized anxiety disorder.

R C Kessler1, M B Keller, H U Wittchen.   

Abstract

The literature reviewed here is consistent in showing that GAD is a common mental disorder that typically has an early age of onset, a chronic course, and a high degree of comorbidity with other anxiety and mood disorders. Comorbid GAD is often temporally primary, especially in relation to mood disorders, and is associated with an increased risk for the subsequent onset and severity of secondary disorders. The weight of evidence reviewed here argues against the view expressed by early commentators that GAD is better conceptualized as a prodrome, residual, or severity marker of other disorders than as an independent disorder. Focused studies of comorbidity between GAD and major depression, in which comorbidity is high, lead to the same conclusion. The crucial evidence for this conclusion includes the following: 1. Contrary to the findings of clinical studies, GAD in the community does not have a higher comorbidity than do most other anxiety or mood disorders. 2. The symptoms of GAD form an empiric cluster distinct from the symptoms of major depression in studies of symptom profiles. 3. Family studies show distinct aggregation of GAD and major depression. 4. Twin studies show that the environmental determinants of GAD are different from the environmental determinants of major depression. 5. The sociodemographic predictors of GAD in epidemiologic studies are different from the predictors of major depression. 6. The clinical course of GAD is less consistently related to comorbidity than is the course of other anxiety and mood disorders. 7. The impairments associated with GAD are equivalent to, or greater than, those associated with other severely impairing chronic physical and mental disorders. These findings show that the status of GAD as an independent disorder is at least as strongly supported by available evidence as is that of other anxiety or mood disorders. This article also shows that uncertainty remains regarding even the basic epidemiologic characteristics of the GAD syndrome. Lingering concerns about the independence of GAD have conspired to exacerbate this problem by promoting repeated changes in the diagnostic criteria for GAD from the DSM-III to DSM-III-R and to DSM-IV. These successive changes have made it difficult to amass consistent long-term data on the natural history of GAD. Available evidence on the empiric validity of current diagnostic thresholds for GAD raises questions about the requirements, such as whether a 6-month minimum duration and four or more additional psychophysiologic symptoms are optimal for identifying all of the people in the general population who suffer from a clinically significant GAD syndrome. An additional source of potential bias in this regard is that the DSM system requires that anxiety be excessive or unrealistic for a diagnosis of GAD. Interestingly, there is no comparable DSM requirement that dysphoria must be excessive or unrealistic to qualify as major depression. These diagnostic uncertainties make it difficult to gain a clear understanding of the true breadth and depth of the GAD syndrome in the general population. Additional research is needed, ideally from unbiased epidemiologic samples, to resolve these basic uncertainties. The strong comorbidity between GAD and major depression, the fact that most people with this type of comorbidity report that the onset of GAD occurred before the onset of depression, and the fact that temporally primary GAD significantly predicts the subsequent onset of depression and other secondary disorders raise the question of whether early intervention and treatment of primary GAD would effectively prevent the subsequent first onset of secondary anxiety and depression. Unfortunately, little is known about this possibility because, as mentioned earlier, few people with pure GAD seek treatment. Why this is true is unknown. Given the early onset of GAD and its strong effects in predicting the subsequent onset, severity, and persistence of other disorders, efforts are needed to collect epidemiologic data on the reasons for the low rate of help seeking among people with pure GAD and to develop outreach strategies that may correct this situation.

Entities:  

Mesh:

Year:  2001        PMID: 11225507     DOI: 10.1016/s0193-953x(05)70204-5

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  61 in total

Review 1.  Comorbidity between and within childhood externalizing and internalizing disorders: reflections and directions.

Authors:  Scott O Lilienfeld
Journal:  J Abnorm Child Psychol       Date:  2003-06

2.  Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys.

Authors:  R C Kessler; N A Sampson; P Berglund; M J Gruber; A Al-Hamzawi; L Andrade; B Bunting; K Demyttenaere; S Florescu; G de Girolamo; O Gureje; Y He; C Hu; Y Huang; E Karam; V Kovess-Masfety; S Lee; D Levinson; M E Medina Mora; J Moskalewicz; Y Nakamura; F Navarro-Mateu; M A Oakley Browne; M Piazza; J Posada-Villa; T Slade; M Ten Have; Y Torres; G Vilagut; M Xavier; Z Zarkov; V Shahly; M A Wilcox
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-27       Impact factor: 6.892

3.  A Fresh Look at Potential Mechanisms of Change in Applied Relaxation for Generalized Anxiety Disorder: A Case Series.

Authors:  Sarah A Hayes-Skelton; Aisha Usmani; Jonathan K Lee; Lizabeth Roemer; Susan M Orsillo
Journal:  Cogn Behav Pract       Date:  2012-08

4.  The burden of generalized anxiety disorder in Canada.

Authors:  Louise Pelletier; Siobhan O'Donnell; Louise McRae; Jean Grenier
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-02       Impact factor: 3.240

5.  Relation between Mastalgia and Anxiety in a Region with High Frequency of Posttraumatic Stress Disorder.

Authors:  Eyüp Murat Yılmaz; Sebahattin Çelik; Harun Arslan; Deniz Değer
Journal:  J Breast Health       Date:  2015-04-01

6.  Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?

Authors:  Atsuo Nakagawa; Michael F Grunebaum; Gregory M Sullivan; Dianne Currier; Steven P Ellis; Ainsley K Burke; David A Brent; J John Mann; Maria A Oquendo
Journal:  Bipolar Disord       Date:  2008-06       Impact factor: 6.744

Review 7.  The neuropsychiatric and neuropsychological features of chronic fatigue syndrome: revisiting the enigma.

Authors:  Yvonne Christley; Tim Duffy; Ian Paul Everall; Colin R Martin
Journal:  Curr Psychiatry Rep       Date:  2013-04       Impact factor: 5.285

Review 8.  Comorbidity of pain and anxiety disorders.

Authors:  Oye Gureje
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

9.  Patient Health Questionnaire Anxiety and Depression Scale: Initial Validation in Three Clinical Trials.

Authors:  Kurt Kroenke; Jingwei Wu; Zhangsheng Yu; Matthew J Bair; Jacob Kean; Timothy Stump; Patrick O Monahan
Journal:  Psychosom Med       Date:  2016 Jul-Aug       Impact factor: 4.312

10.  The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic.

Authors:  Jeffrey R Strawn; Thomas D Geracioti
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.